Barclays lowered the firm’s price target on Regeneron (REGN) to $1,080 from $1,220 and keeps an Overweight rating on the shares. The firm reset Eylea estimates on the Pavblu generic launch and modestly lowered second half of 2204 Dupixent estimates. However, there are some reasons to believe the stock’s overhangs are removed with a now-improved setup into near-term catalysts, As previously reported,
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Amgen to launch U.S. Eylea biosimilar, Reuters reports
- Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
- RBC would buy Regeneron on weakness with biosimilar Eylea priced in
- Regeneron announces three-year data for EYLEA HD Injection 8 mg study
- Regeneron price target lowered to $1,137 from $1,200 at Truist